Global Drug Addiction Treatment Market – Industry Trends and Forecast to 2030

Global Drug Addiction Treatment Market, By Types (Opioid Addiction, Benzodiazepine Addiction, Barbiturate Addiction and Others), Treatment (Therapy, Medication and Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.

Drug Addiction Treatment Market Analysis and Size

Drug overdose is among the top causes of mortality globally. According to records of Centers for Disease Control and Prevention (CDC), more than 91,000 individuals died in 2020 because of drug overdose in the U.S. Several responses of governments provide a multitude of unique perspectives on how to manage the addicts, eliminate stigma linked with substance usage, and starve the underground markets. Numerous companies are advancing medicinal therapy's use to treat opioid-use disorders in novel and more efficient ways.

Data Bridge Market Research analyses a growth rate in the drug addiction treatment market in the forecast period 2023-2030. The expected CAGR of drug addiction treatment market is tend to be around 7.3% in the mentioned forecast period. The market was valued at USD 17522.69 million in 2022, and it would grow up to USD 30,789.21 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Drug Addiction Treatment Market Scope and Segmentation

Market Definition

Drug addiction is also known as substance use disorder, a mental health disorder wherein a patient cannot control the use of drugs or any medications or substance. Drug addiction treatment is meant to help patients to limit the use of abuse drugs. Drug abuse is when an individual consumes legal or illegal substances. Whereas addiction is when an individual fails in discontinuing the consumption of these drugs.

Drug Addiction Treatment Market Dynamics

Drivers

• Growing Awareness about Drug addiction

To increase the customer pool, drug abuse treatment providers and manufacturers primarily focus on creating awareness among people and drug store owners about the severe effects of drug abuse and the importance of abuse treatment. Increasing awareness through television advertisements, information brochures, newspapers, and other media has proved to be very effective in impeding the substance abuse crisis to a certain extent.

• Growing Partnerships Between Organizations

There are several organizations that are participating in several organizations that are boosting the growth of the market. For instance, in March 2016, GlaxoSmithKline partnered with 2morrow Inc., developer of SmartQuit app to supply patches to smokers having the app plan. In August 2013, the company agreed with Amneal Pharmaceuticals LLC to distribute its Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII), a generic version of Suboxon, to addiction treatment centers.

Opportunities

• Stress on Addiction Treatment Laboratories     

The addiction crisis over the past decade has augmented the need to invest in integrated R&D activities which focus on addiction treatment and the recovery process. Although the number of research activities pertaining to issues related to addiction has increased at an impressive pace, stakeholders operating in the current addiction treatment market landscape are progressively finding new methods to implement these findings into the real-world care delivery.

• Increased Government Initiatives and Funding

In countries such as the U.K., the National Health Service (NHS) runs numerous public and privately funded programs for treating substance addiction. Furthermore, several companies adopt merger & acquisition strategies to enlarge market presence in new geographies or add new products and services or both to existing platforms. For instance, in December 2015, Acadia Healthcare acquired Priory Group, which is a leading provider of behavioral care services in the U.K. This acquisition was envisioned to expand Acadia Healthcare’s capacity and geographic presence in the U.K.

Restraints/Challenges

• Reluctance Among Patients Of Drug-Use Disorder

Major reluctance among patients of substance-use disorder is a major factor limiting revenue growth of the market. According to the National Survey on Drug Use and Health (NSDUH), more than 14% of individuals over the age of 12 with Substance-Use Disorder (SUD) sought treatment in 2020. In addition to this, slow rise in number of patients who are seeking help for improving mental health as a consequence of addiction and drug overuse is suggestive of reluctance of patients to seek medical help because of taboo and hesitation associated with consequences of substance use

• High Cost of Treatment

The increased expenditure required for the diverse treatment processes impedes market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This drug addiction treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug addiction treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development:

• On 2022, Pfizer, Inc. announced a new strategic partnership with Alex Therapeutics to customize treatment through digital therapeutics and use AI-based platform of the latter company for providing Cognitive Behavioral Therapy (CBT) and Acceptance and Commitment Therapy (ACT) to patients of nicotine addiction.
• On 2022, Indivior PLC. entered into a collaborative agreement with Addex Therapeutics, a clinical-stage pharmaceutical company, for discovery and development of novel oral gamma-aminobutyric acid subtype B (GABAB) Positive Allosteric modulator (PAM) drug candidates. Under this agreement, Indivior will provide the latter company with round USD 900,000 as additional research funding.

Global Drug Addiction Treatment Market Scope

The drug addiction treatment market is segmented on the basis of types, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Opioid Addiction
• Benzodiazepine Addiction
• Barbiturate Addiction
• Others

Treatment

• Therapy
• Medication
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Drug Addiction Treatment Market Regional Analysis/Insights

The drug addiction treatment market is analyzed and market size insights and trends are provided by types, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the drug addiction treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is dominating the market due to the focus of global players on novel technology or formulation of existing drugs.

Asia-Pacific is considered to grow over the coming years due to high prevalence of drug addiction and number of generic drugs.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data. 

Competitive Landscape and Global Drug Addiction Treatment Market  Share Analysis

The drug addiction treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to drug addiction treatment market

Key players operating in the drug addiction treatment market include:

• Takeda Pharmaceutical Company Limited (Japan)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbott (U.S.)
• Medtronic (Ireland)
• Abbott (U.S.)
• BD (U.S.)
• Johnson & Johnson Services, Inc.(U.S.)
• GSK Plc. (U.K.)
• Bayer AG (Germany)
• Zimmer Biomet (U.S.)
• Stryker Corporation (U.S.)
• Homology Medicines, Inc (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• JCR Pharmaceuticals Co., Ltd. (Japan)
• Sangamo Therapeutics (U.S.)
• AVROBIO, Inc (U.S.)
• REGENXBIO Inc (U.S.)
• CANbridge Life Sciences Ltd. (Taiwan)
• Denali Therapeutics (U.S.)
• Jasper Therapeutics, Inc. (U.S.)